CISPLATIN + AZD-1775 In Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-negative Metastatic Breast Cancer
Interventions: DRUG: Cisplatin|DRUG: AZD1775
Sponsor: Dana-Farber Cancer Institute
Collaborators: AstraZeneca